NorthWest Biotherapeutics Inc (NWBO)

[gpb]

It's a well-documented concern, but at least in their Phase I/II trials the patients got standard of care plus DCVax-L, not just the vaccine. So while I'm concerned about the protocol being potentially biased against immunotherapies, the earlier trials seem to indicate it's at least possible for there to be a substantial treatment advantage in spite of that. If successful with proving this advantage (like the 6 months required to meet the primary endpoint in the current trial or like the 18 months seen in the earlier patients), it then becomes a lot easier to start collecting data on solo immunotherapy. This is mentioned in the following comment on one of the SA articles:
http://seekingalpha.com/article/1907681-sorting-out-thorny-issues-in-the-latest-northwest-bio-immunocellular-controversy#comment-27423611